Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Conference, Product/Service, Trade Show

Hologic to Showcase Developments in Next-Generation AI Solutions at RSNA 2023


Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 26 to 30. On the show floor and during multiple workshops, the global leader in breast imaging will unveil advances that leverage AI to improve cancer detection, workflow and patient satisfaction.

New to Hologic's portfolio of Breast and Skeletal Health Solutions is its Genius AI® Detection 2.0 solution, a next-generation deep-learning technology designed to improve breast cancer detection while reducing the number of false-positive markings per case. With more than a 70% reduction in false-positive markings per case when compared to Hologic's ImageChecker ® CAD solution, Genius AI Detection 2.0 technology gives radiologists confidence that marked lesions are truly suspicious and warrant further review.1 Additionally, the new SecurView® 12.0 solution enables more multimodality capabilities, including reading breast ultrasound cases directly in the SecurView viewer. When paired with Genius AI Detection 2.0, the new automated lesion correlation feature is enabled to allow for faster review of specific lesions.

"We are building on our history of innovation in breast health with an exciting new AI-based solution that is designed to support the radiologist with improved cancer detection and a more efficient workflow ? two factors that we know are critical for our customers," said Erik Anderson, Division President, Breast and Skeletal Health Solutions, Hologic. "At this year's RSNA meeting, we're looking forward to engaging with industry leaders and affirming our commitment to advancing breast health through cutting-edge technology."

Genius AI Detection 2.0 technology represents Hologic's continued commitment to advancing and refining its AI roadmap. Customer feedback, research findings and continuous improvements will inform future iterations of Genius AI Detection technology, as well as new AI products. Hologic is currently exploring new product features to drive toward even greater accuracy and efficient breast care, including:

In the South Hall, Level 3, Booth 1919 at McCormick Place, guests can experience Hologic's comprehensive portfolio, including the Dimensions® mammography portfolio, Affirm® Contrast Biopsy software, I-View® Contrast Enhanced Mammography software and a full suite of breast biopsy and surgery solutions. Additionally, the Company will host a CME-accredited symposium and lunch-and-learn sessions, including:

About Hologic, Inc.

Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include the world's first commercial 3D Mammographytm system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

For more information on Hologic, visit www.hologic.com.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Hologic, Genius AI, ImageChecker, I-View, LOCalizer, SecurView, Tuloc, Tuflex and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

1 Kshirsagar, A. (2023). Comparison between ImageChecker CAD and GAID algorithm on sequestered FDA database. Refer to Hologic document (DHM-14593).

Source: Hologic, Inc.


These press releases may also interest you

at 10:00
With an aim to spotlight influential figures who have significantly shaped the contours of digital marketing, ClickReady's new blog series...

at 10:00
Having led over a decade of successful WordPress projects, Inspry has proven itself as a reliable technical...

at 00:45
Claudio Bono, Managing Director for two independent Hotels in Silicon Valley, is thrilled to unveil a groundbreaking platform and an idea that will transform the landscape of the urgent unhoused crisis and social issues. Leveraging his extensive...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Side Protocol with the OKX Wallet. Side Protocol is a cross-chain middleware protocol designed to enable seamless communication and asset transfer between heterogeneous...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

26 avr 2024
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...



News published on and distributed by: